Abstract: A method and conditioning system for conditioning exhaust gas are provided. The conditioning system includes one or more heat removal systems for removing heat from an exhaust gas. The conditioning system also includes a condensate removal system fluidly coupled with, and positioned downstream of, the one or more heat removal systems. The condensate removal system is operable to remove moisture from the exhaust gas. In some variants, the conditioning system further includes one or more fluid chambers fluidly coupled with, and positioned downstream of, the condensate removal system. Each fluid chamber defines an interior in which a capture medium is contained. The cooled, moisture-depleted exhaust is selectively distributed to the fluid chambers to allow for harvesting or capture of a set of target species from the exhaust gas.

Abstract: A method and conditioning system for conditioning exhaust gas are provided. The conditioning system includes one or more heat removal systems for removing heat from an exhaust gas. The conditioning system also includes a condensate removal system fluidly coupled with, and positioned downstream of, the one or more heat removal systems. The condensate removal system is operable to remove moisture from the exhaust gas. In some variants, the conditioning system further includes one or more fluid chambers fluidly coupled with, and positioned downstream of, the condensate removal system. Each fluid chamber defines an interior in which a capture medium is contained. The cooled, moisture-depleted exhaust is selectively distributed to the fluid chambers to allow for harvesting or capture of a set of target species from the exhaust gas.

Abstract: A method and conditioning system for conditioning exhaust gas are provided. The conditioning system includes one or more heat removal systems for removing heat from an exhaust gas. The conditioning system also includes a condensate removal system fluidly coupled with, and positioned downstream of, the one or more heat removal systems. The condensate removal system is operable to remove moisture from the exhaust gas. In some variants, the conditioning system further includes one or more fluid chambers fluidly coupled with, and positioned downstream of, the condensate removal system. Each fluid chamber defines an interior in which a capture medium is contained. The cooled, moisture-depleted exhaust is selectively distributed to the fluid chambers to allow for harvesting or capture of a set of target species from the exhaust gas.

Abstract: A biphasic system and method for assisting breathing of a patient by controllably providing breathing gas to the patient and taking exhaled gas from the patient during inspiration and expiration phases. The system and method having a pair of pressure-controlling means such as hydrostatic pressures or pop-off valves that are coupled to the patient breathing interface. Various means for controlling gas pressure at the breathing interface are described.

Abstract: A broadcast control apparatus for visual data includes a touch screen display panel operable to receive and display visual data simultaneously in real time from a plurality of visual sources. It also includes a touch screen graphical panel for the retrieval of control functions from a control function register. The visual data from at least one of the visual sources is selectable for use by finger pressure on the associated portion of the touch screen display panel and the selected data is modifiable in accordance with the retrieved control function.

Abstract: A broadcast control apparatus for visual data includes a touch screen (32, 34) display panel operable to receive and display visual data simultaneously in real time from a plurality of visual sources. It also includes a touch screen graphical panel for the retrieval of control functions from a control function register. The visual data from at least one of the visual sources is selectable for use by finger pressure on the associated portion of the touch screen (32, 34) display panel and the selected data is modifiable in accordance with the retrieved control function.

Abstract: A broadcast control apparatus for visual data includes a touch screen (32, 34) display panel operable to receive and display visual data simultaneously in real time from a plurality of visual sources. It also includes a touch screen graphical panel for the retrieval of control functions from a control function register. The visual data from at least one of the visual sources is selectable for use by finger pressure on the associated portion of the touch screen (32, 34) display panel and the selected data is modifiable in accordance with the retrieved control function.

Abstract: A broadcast control apparatus for visual data includes a touch screen (32, 34) display panel operable to receive and display visual data simultaneously in real time from a plurality of visual sources. It also includes a touch screen graphical panel for the retrieval of control functions from a control function register. The visual data from at least one of the visual sources is selectable for use by finger pressure on the associated portion of the touch screen (32, 34) display panel and the selected data is modifiable in accordance with the retrieved control function.

Abstract: Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

Abstract: Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein X is bromo or iodo, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

Abstract: Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein X is bromo or iodo, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

Abstract: Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

Abstract: A broadcast control apparatus for visual data includes a touch screen (32, 34) display panel operable to receive and display visual data simultaneously in real time from a plurality of visual sources. It also includes a touch screen graphical panel for the retrieval of control functions from a control function register. The visual data from at least one of the visual sources is selectable for use by finger pressure on the associated portion of the touch screen (32, 34) display panel and the selected data is modifiable in accordance with the retrieved control function.

Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

Abstract: This invention relates to an ink jet printing method comprising the steps of: A) providing an ink jet printer that is responsive to digital data signals; B) providing an ink jet printhead comprising a nozzle array comprising a plurality of nozzles, said nozzle array being dedicated to ejecting a given ink jet ink composition, wherein said nozzles are 20 microns or less in diameter; C) supplying said printhead with said given ink jet ink composition, said ink jet ink composition comprising particles wherein at least 90% by weight of said particles have a diameter that is less than 1/120th of the diameter of said nozzles; and D) printing using said given ink jet ink composition in response to said digital data signals.

Abstract: The invention relates a nucleic acid and its encoded polypeptide ESM-1, whose expression is modulated in angiogenesis and oncogenesis. The invention also relates to antibodies having specificity for said polypeptide. The present invention also relates to antisense molecules. The invention further relates to methods useful for treating or modulating angiogenesis in mammals in need of such biological effect.

Abstract: The invention relates generally to the identification of nucleic acids and their encoded polypeptides, particularly VCC1, whose expression is modulated in angiogenesis. These nucleic acids and proteins have not previously been identified as having a biological role in angiogenesis. The invention further relates to compounds that modulate VCC1 expression and/or activity. Methods of using these compounds for modulation of VCC-1 expression and for treatment of diseases associated with expression of VCC-1 are provided. Also included are methods of diagnosis of VCC1 associated angiogenic disorders.